Research programme: anthrax vaccine - Altimmune

Drug Profile

Research programme: anthrax vaccine - Altimmune

Alternative Names: AdVAV; NasoShield

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Vaccines
  • Mechanism of Action Anthrax toxin modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Intranasal)
  • 01 Sep 2015 Vaxin is now called Altimmune
  • 29 Apr 2015 Pharmacodynamics data from a preclinical study in anthrax infections released by TAXIS Pharmaceuticals (9178226; 3126526)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top